Low-dose azacitidine, pioglitazone and all-<i>trans</i> retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase

• Daniel Heudobler,
• Florian Luke,
• Joachim Hahn,
• Matthias Grube,
• Pavla Schlosser,
• Stephan Kremers,
• Thomas Sudhoff,
• Jorg Westermann,
• Marie Luise Hutter-Kronke,
• Richard F. Schlenk,
• Daniela Weber,
• Peter Paschka,
• Florian Zeman,
• Hartmut Dohner,
• Wolfgang Herr,
• Albrecht Reichle,
• Simone Thomas

Affiliations

Daniel Heudobler

University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology, Germany; Bavarian Center for Cancer Research, University Hospital Regensburg, Regensburg

Florian Luke

University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology, Germany; Division of Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg

Joachim Hahn

University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology

Matthias Grube

University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology

Pavla Schlosser

University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology

Stephan Kremers

Caritaskrankenhaus Lebach, Department of Hematology/Oncology

Thomas Sudhoff

Klinikum Passau, Department Hematology and Oncology

Jorg Westermann

Charite- University Medical Center Berlin- Department of Hematology, Oncology and Tumor Immunology, Campus Virchow-Klinikum, Berlin

Marie Luise Hutter-Kronke

Charite- University Medical Center Berlin- Department of Hematology, Oncology and Tumor Immunology, Campus Virchow-Klinikum, Berlin, Germany; University Hospital Ulm, Department of Internal Medicine III

Richard F. Schlenk

National Center of Tumor Diseases Trial Center, German Cancer Research Center and Heidelberg University Hospital, Heidelberg, Germany; Heidelberg University Hospital, Department of Internal Medicine V, Heidelberg

Daniela Weber

University Hospital Ulm, Department of Internal Medicine III

Peter Paschka

University Hospital Ulm, Department of Internal Medicine III

Florian Zeman

Center for Clinical Studies, University Hospital Regensburg, Regensburg

Hartmut Dohner

University Hospital Ulm, Department of Internal Medicine III

Wolfgang Herr

University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology

Albrecht Reichle

University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology

Simone Thomas

University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology, Germany; Leibniz Institute for Immunotherapy, Division of Genetic Immunotherapy, Regensburg